SR-17018
Limited data
Limited data
Sparse data. Doses and effects may be unreliable or untested.
- 1 source
- duration data present
- 19 combo interactions documented
- classified Research-chemical
- dose data not in PW/TripSit (unverifiable)
- 1 source
- duration data present
- 19 combo interactions documented
- classified Research-chemical
- dose data not in PW/TripSit (unverifiable)
Aliases: 5,6-dichloro desmethylchlorphine
Summary
Sold solely as a research chemical with no quality control or clinical data in humans. SR-17018 is not orally bioavailable when dissolved in water due to poor solubility; must be taken as powder or with appropriate excipients. Primarily reported for opioid tapering due to craving suppression and tolerance reduction properties, not recreation.
Dose Information
Dose basis. The dose figures on this page are not clinical data. They are aggregated from community reports by a secondary source whose own notes state there is no human pharmacokinetic study behind them, and our internal audit flags this substance's dosing as unverifiable. Treat them as a rough orientation, not a safe range. Assume full respiratory depression, keep naloxone to hand, never dose alone, and never combine with benzodiazepines, alcohol or other depressants.
| ROA | Threshold |
|---|---|
| Oral | 0.5mg |
| Sublingual | 0.25mg |
Only a threshold dose is documented for this substance β the smallest amount with a noticeable effect. There is no published light/common/strong ladder to show above it.
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | Total |
|---|---|---|---|---|---|
| Oral | 15-45 min | 30-60 min | 1-3 hrs | 4-6 hrs | 5.75-10.75 hrs |
| Sublingual | 10-30 min | 20-45 min | 1-3 hrs | 4-6 hrs | 5.5-10.25 hrs |
Effect Profile
Scores (1–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Moderate euphoria and itching/nausea with mild pain relief, low sedation
Add to PsychonautWiki Journal
The PsychonautWiki Journal logging app doesn't include every substance. To track SR-17018 there, start adding an ingestion, search for the name, and choose to add it as a custom substance. Paste these values:
SR-17018 Source: SubstanceSearch (substancesearch.com) Oral dose (mg): threshold 0.5 Sublingual dose (mg): threshold 0.25 Oral duration: onset 15-45m Β· come-up 0.5-1h Β· peak 1-3h Β· offset 4-6h Β· total 5.75-10.75h Β· after-effects 2-4h Sublingual duration: onset 10-30m Β· come-up 20-45m Β· peak 1-3h Β· offset 4-6h Β· total 5.5-10.25h Β· after-effects 2-4h Note: ranges are harm-reduction guidance, not a prescription. Start low, go slow, and test your substances.
The app keeps custom substances simple, so the full dose ranges live in the description text above. Ranges are harm-reduction guidance, not a prescription.
Tolerance
Tolerance Decay
Acute tolerance: develops within a single session β the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Model reflects preclinical evidence for relatively slower tolerance build than morphine in some assays and community reports of tolerance reduction during SRβ17018 use; human kinetics unknown. Values are heuristic for harmβreduction planning, not physiological truths.
Cross-Tolerances
Effects
- Pain relief
- Physical euphoria
- Stimulation
- Nausea
- Respiratory depression
- Increased heart rate
- Teeth grinding
- Sedation
- Itchiness
- Cognitive euphoria
- Craving suppression
- Anxiety suppression
- Wakefulness
- Focus enhancement
- Motivation enhancement
- Constipation
- Dizziness
- Anxiety
- Cognitive fatigue
- Tactile enhancement
- Color enhancement
- Increased music appreciation
- Appetite suppression
- Light sensitivity
- Disinhibition
- Dulled perception
- Increased sexuality
- Visual and auditory hallucinations
- Drifting
Combinations
Cross-Check SR-17018 with another substanceHelpful Links
Report an issue or suggest an edit
Spotted incorrect or dangerous information, have a correction, a new study, or a useful addition for SR-17018? Let us know. Reports are reviewed by moderators — this is not posted publicly.